Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

Inclusion Criteria: * HER-2/neu overexpression assessed by FISH test or with immunohistochemical methods: Dako(the result must be 3+ with dakotest); if the immunohistochemical test results 2+ it is needed a positive FISH test * Female \< 70yrs * Histologically or cytologically proven breast cancer. * Metastatic or locally advanced breast cancer (clinical stage: III-IV) * Adequate hematological, hepatic, renal and cardiac function, the latter confirmed by echocardiography with FEVS ≥50% * Prior adjuvant chemotherapy if doxorubicin total dose ≤300 mg/m2, epirubicin total dose ≤450 mg/m2 Exclusion Criteria: * History of cardiopathy * Severe hepatic and renal diseases * Brain metastases as the only parameter of disease * Contraindication to the use of corticosteroids as premedication * Acute infectious diseases * Insulin-dependent diabetes * History of other cancers except for adequately treated basal cell skin cancer or in situ carcinoma of the cervix * Concurrent treatment with any other cancer therapy